With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Marble Falls, Texas - New telemedicine solution offers accessible, personalized weight management. Victory Select, the ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

to ensure that they are ready to seek out and commit to GLP-1 therapy — and continue to have the emotional, mental, and even socioeconomic capacity to stay on medication for the long haul.

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people ... Eli Lilly has another approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla ...